Ownership and insider activity for Equillium, Inc. (EQ): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor.
Price
| Price | $1.89 |
| Market Cap | $119M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-05 | Zedelmayer Christine | M-Exempt | 14,584 | $11K |
| 2026-06-05 | Zedelmayer Christine | S-Sale | 14,584 | $43K |
| 2026-06-05 | Zedelmayer Christine | M-Exempt | 14,584 | $11K |
| 2026-06-04 | Connelly Stephen | S-Sale | 200,000 | $633K |
| 2026-06-05 | Connelly Stephen | S-Sale | 30,975 | $91K |
| 2026-05-28 | Tom Penny | M-Exempt | 65,000 | $51K |
| 2026-05-28 | Tom Penny | S-Sale | 65,000 | $192K |
| 2026-05-28 | Tom Penny | M-Exempt | 65,000 | $51K |
| 2026-05-28 | DEMSKI MARTHA J | A-Award | 70,000 | $199K |
| 2026-05-28 | Pruzanski Mark | A-Award | 70,000 | $199K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.1M | $28.5M | $13.2M | $24.0M | $50.4M | $59.1M | $23.2M | $18.1M | $30.3M |
| Short-term Investments | 0 | $37.4M | $39.9M | $58.2M | $30.3M | $11.9M | $17.6M | $4.5M | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | $4.1M | $6.3M | $1.1M | $108000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $7.1M | $67.2M | $55.5M | $85.2M | $83.4M | $76.7M | $49.3M | $25.0M | $30.3M |
| Property, Plant & Equipment | $2077 | $63515 | $93000 | $239000 | $1.9M | $1.6M | $1.1M | $626000 | $658000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $7.2M | $67.2M | $55.5M | $85.4M | $85.4M | $78.4M | $50.5M | $25.6M | $31.9M |
| Accounts Payable | $243741 | $1.1M | $1.9M | $2.8M | $1.2M | $4.0M | $4.7M | $2.7M | $755000 |
| Short-term Debt | 0 | 0 | 0 | $1.7M | $1.4M | $5.7M | 0 | $197000 | $363000 |
| Total Current Liabilities | $568820 | $2.0M | $3.9M | $7.2M | $8.9M | $32.0M | $27.6M | $6.4M | $2.9M |
| Long-term Debt | $8.1M | 0 | $9.7M | $8.3M | $8.8M | $3.2M | 0 | 0 | $356000 |
| Total Liabilities | $9.4M | $2.2M | $13.7M | $15.6M | $18.9M | $46.5M | $28.0M | $6.5M | $3.3M |
| Retained Earnings | -$2.3M | -$15.5M | -$41.1M | -$70.9M | -$110.0M | -$172.4M | -$185.7M | -$193.8M | -$216.2M |
| Total Equity | -$2.3M | $64.9M | $41.8M | $69.9M | $66.5M | $31.9M | $22.6M | $19.1M | $28.6M |
| Total Debt | $8.1M | $200000 | $9.7M | $9.9M | $11.8M | $10.2M | $824000 | $384000 | $719000 |
| Net Debt | $955313 | -$65.7M | -$43.5M | -$72.2M | -$68.9M | -$60.8M | -$40.0M | -$22.2M | -$29.6M |
| Working Capital | $6.6M | $65.1M | $51.7M | $77.9M | $74.5M | $44.7M | $21.8M | $18.6M | $27.3M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 23.40 |
Profitability
| Return on Equity | -41.15% |
| Return on Invested Capital | -34.10% |
| Return on Assets | -30.70% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: COEP · CUE · FBIO · IPSC · MDCX · NRXP · OSTX
Explore sector: Healthcare · Biotechnology
More sections of EQ: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks